[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-participant-study\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-participant-study":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100636963","slowly-digestible-carbohydrates-for-glp-1-secretion-100636963",false,"NCT07572513","Slowly Digestible Carbohydrates for GLP-1 Secretion","Inclusion Criteria:\n\n1. Healthy population\n2. BMI between 18.5 and 24.9 kg\u002Fm2\n3. Adults 18 - 45 years old\n4. Men or women\n5. Able to read\u002Fspeak English\n6. Fasting blood glucose levels ≤100 mg\u002FdL\n7. HbA1c ≤ 5.7%\n\nExclusion Criteria:\n\n1. Participants with 18 \\> Years of Age \\> 45 will be excluded.\n2. Subjects with 18.5 kg\u002Fm² \\> BMI \\> 24.9 kg\u002Fm² will be excluded.\n3. Diabetic individuals will be excluded.\n4. Individuals with history of gastrointestinal disease will be excluded from the study.\n5. Pregnant or nursing women will also be excluded.\n6. Individuals taking GLP-1 medications, or on weight-loss diets or restrictive eating patterns.\n7. Individuals suffering from dairy or gluten intolerance or allergies will be excluded.",true,"ALL","18 Years","45 Years",{"count":20,"type":21},19,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss.\n\nResearchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 60, 120, 180 minutes and after a second meal.\n\nThere will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will:\n\n* Consume a randomized test beverage (SDC or maltodextrin)\n* Receive a blood draw at 7 timepoints over 3 hrs\n* Take a satiety questionnaire 5 times over 3 hrs\n* Consume a standardized lunch 3 hrs after the test beverage consumption",[27,28,29,30,31],"Blood Glucose","GLP-1","Satiety","Second Meal Intake","Healthy Participant Study",[28,33,34,35,29,36,37,27],"Slowly-Digestible Starch","Ileal-Digesting Starch","Dietary Starch","Starch","raw corn starch","RECRUITING","2026-05-01",{"date":41,"type":42},"2026-05-07","ACTUAL",{"date":39,"type":21},{"date":45,"type":21},"2026-11-25",{"name":47,"class":48},"Purdue University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":49},"100625372","phase-1-a-multiple-ascending-dose-study-evaluating-the-safety-and-tolerability-of-a-novel-formulation-of-qrl-101-in-healthy-participants-100625372","NCT07421778","A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants","A Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel Formulation of QRL-101 in Healthy Participants","Inclusion Criteria:\n\n1. Age 18 to 65 years of age inclusive at the time of signing the informed consent.\n2. Clinical chemistry laboratory values within acceptable range for the population, as per investigator judgment.\n3. Body mass index of 18 to 32 kg\u002Fm2 (inclusive).\n4. Willing and able to practice effective contraception.\n\nExclusion Criteria:\n\n1. Currently enrolled in any other clinical trial involving a study drug or off-label use of a drug or device, or any other type of medical research judged not to be scientifically or medically compatible with this study.\n2. Any participant in \\>4 studies a year and\u002For has participated in a clinical trial within 1 month of the expected dosing date.\n3. History or presence of medical illness including, but not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine, psychiatric, or neurological disease, convulsions, or any clinically significant laboratory abnormality that, in the judgment of the investigator, indicate a medical problem that would preclude study participation.","65 Years",{"count":59,"type":21},48,[61],"PHASE1","QRL-101-08 is a multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of a novel formulation of QRL-101 in healthy participants.",[31],"2026-02-12",{"date":66,"type":42},"2026-02-19",{"date":68,"type":42},"2026-02-02",{"date":70,"type":21},"2026-08-31",{"name":72,"class":73},"QurAlis Corporation","INDUSTRY",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":49},"100616375","phase-1-this-is-a-phase-1-randomized-single-blind-placebo-controlled-study-to-assess-the-safety-pharmacokinetics-pk-and-pharmacodynamics-pd-of-beam-103-in-healthy-subjects-100616375","NCT07304791","This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects","A Randomized, Single-Blind, Placebo-Controlled, Phase 1 Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BEAM-103 in Healthy Subjects","Inclusion Criteria:\n\n* Ages 18 to ≤55 years\n* Body mass index (BMI) of 18.5 to 25 kg\u002Fm2\n* Morning neutrophil count ≥2.6 × 109 cells\u002FL for Black\u002FAfrican American subjects or ≥3.5 ×109 cells\u002FL for Caucasian\u002FOther subjects\n* Baseline hemoglobin value of ≥14 g\u002FdL for males and ≥12 g\u002FdL for females\n* Baseline platelet count of \\>150 × 109\u002FL.\n* Subjects must be in general good health without significant medical conditions (based on physical exam, electrocardiogram (ECG), and laboratory test results with no clinically significant deviations), per the investigator's assessment\n\nExclusion Criteria:\n\n* Known hypersensitivity to any component of the investigational medicinal product (IMP).\n* Participation in another clinical trial involving treatment with an investigational agent within 90 days of informed consent is prohibited.\n* Positive serum pregnancy test or breastfeeding at screening (female participants).\n* Live virus vaccination within 4 weeks prior to signing informed consent.\n* Any severe or uncontrolled medical condition (eg. severe asthma or severe peanut allergy) that in the opinion of the investigator would put the subject at undue medical risk or impair the ability to interpret study results.","55 Years",{"count":83,"type":21},30,[61],"The purpose of this Phase I single ascending dose study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of BEAM-103 in healthy subjects between the ages of 18 and 55. The main questions the study aims to answer are:\n\n* Safety and tolerability of BEAM-103\n* The pharmacokinetic (PK) profile and pharmacodynamic (PD) characteristics of EAM-103\n* The effect of BEAM-103 on hematologic parameters\n* To assess the immunogenicity of BEAM-103\n\nResearchers will determine and establish the therapeutic window of the antibody and select optimal doses for future trials in patients.\n\nSubjects will:\n\n* Be asked to participate in the study for a duration of 4-5 months total\n* Be asked to sign informed consent\n* Be assessed for eligibility\n* Provide medical and medication history\n* Receive a single intravenous infusion of BEAM-103 or placebo on study Day 1 according to their assigned cohort\n* Be followed up to 4 months after infusion",[87,31],"Healthy Subjects",[89,90],"ESCAPE","BEAM-103","2025-12-12",{"date":93,"type":42},"2025-12-26",{"date":95,"type":42},"2025-10-27",{"date":97,"type":21},"2026-05-29",{"name":99,"class":73},"Beam Therapeutics Inc."]